Starting dose selection is usually based on patient characteristics and established biomarkers for treatment response, including AMH and AFC, Day 3 follicle-stimulating hormone (FSH), age, body weight, response to any previous ovarian stimulation cycle (ovulation induction [OI] gonadotropin and/or ART treatment) and any specific diagnoses relating to subfertility (including polycystic ovary syndrome [PCOS], amenorrhea, thyroid stimulating hormone levels and conditions of the Fallopian tubes) [14–19]. This evidence concerns the gene BRD2 and polycystic ovary syndrome.